Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
Amid the war on obesity, a clear winner has emerged in a battle between two weight-loss injectables. Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide),
In new trial, Zepbound bests Wegovy for weight loss
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical trial funded by Lilly.
Zepbound leads to more weight loss than Wegovy, Eli Lilly says
Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.
Eli Lilly's Zepbound beats Wegovy in head-to-head weight loss trial
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in a study.
Eli Lilly's Zepbound Tops Novo Nordisk's Wegovy in Weight-Loss Trial
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, according results of the study released Wednesday.
Zepbound Outperforms Wegovy in Weight Loss Clinical Trial
Zepbound outperformed Wegovy for weight loss in a new clinical trial funded by Eli Lilly & Co., Zepbound's maker.
New study compares weight loss drugs Wegovy and Zepbound
A new study is out that compares the effectiveness of two popular weight loss drugs, Wegovy and Zepbound. The study, which was conducted by Eli Lilly, the maker of Zepbound, found that weight loss with Zepbound was significantly more than Wegovy.
Prescription fills for weight loss drugs Zepbound and Wegovy more than doubled in 2024, GoodRx says
The jump in prescription fills comes despite limited insurance coverage and high out-of-pocket costs for Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
Zepbound leads to more weight loss than Wegovy, drugmaker Eli Lilly says
Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from drugmaker Eli Lilly.
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Weed and Weight Loss?
Cannabis might help with weight loss by targeting the endocannabinoid system, potentially suppressing appetite, boosting metabolism, and offering new, less invasive treatments for obesity and
Ozempic cuts drinking, Zepbound beats Wegovy, and a blood test detects 50 cancers: Pharma news roundup
Some patients taking weight-loss drugs, including popular GLP-1 treatments like Ozempic (NVO) and Wegovy, reported reducing ...
WebMD8d
Wegovy vs. Zepbound: New Data Declares a Winner
Dec. 4, 2024 – People taking the weight loss drug Zepbound experienced dramatically greater weight loss than competitor Wegovy in the first head-to-head trial. Those who took Zepbound lost on ...